TWO DOSES OF A NEW IMMUNOTHERAPY CLEARED A CHILD'S LIVER CANCER.

Researchers at Texas Children's, Baylor College of Medicine and Seattle Children's reported in the New England Journal of Medicine that a child with hepatoblastoma had complete regression of disease after a novel immunotherapy given as part of the CARE study.

A child treated on the CARE study had complete regression of liver cancer after a novel immunotherapy, reported in the New England Journal of Medicine by Texas Children's, Baylor College of Medicine and Seattle Children's.

WHAT HAPPENED

Texas Children's announced in September 2026 that a report in the New England Journal of Medicine, from researchers at Texas Children's, Baylor College of Medicine and Seattle Children's, describes complete regression of liver cancer in a child treated with a novel immunotherapy as part of the CARE study.

WHY THIS IS HOPESLOP

One case is one case. But a hepatoblastoma that disappears is the kind of result that turns an experimental idea into a next trial, and the next trial into a standard of care. Somewhere there is a family whose scans came back with nothing on them.

ORIGINAL SOURCETexas Children's HospitalRead the original report

MORE HOPESLOP

SEE THE DAILY ARCHIVE →